Adhesion of HT-29 Colon Carcinoma Cells to Endothelial Cells Requires Sequential Events Involving E-selectin and Integrin Beta4
Overview
Affiliations
HT-29 colon carcinoma cells attach to TNFalpha-activated human umbilical vein endothelial cells (HUVECs) by their specific binding to E-selectin. This interaction activates, in the cancer cells, the MAPK SAPK2/p38, which leads to their transendothelial migration (Laferrière et al., J Biol Chem 2001; 276: 33762). In this study, we investigated the role of E-selectin in activating integrins to modulate adhesion and regulate integrin-mediated events. Blocking the integrins from HT-29 cells (alpha2, alpha3, alpha6, alphav/beta5, beta1 and beta4) with specific antibodies revealed a role for beta4 integrin in their adhesion to TNFalpha-treated HUVEC. The beta4 integrin-dependent adhesion was maximal after 30 min, whereas the-E-selectin-dependent adhesion was maximal after 15 min. Integrin beta4 became quickly phosphorylated upon addition of HT-29 cells to endothelial cells and the effect was independent of the expression of E-selectin. Moreover, a recombinant E-selectin/Fc chimera did not induce the phosphorylation of beta4. The phosphorylation of beta4 is not required for adhesion since adhesion was not affected in HT-29 cells that express a truncated form of beta4 that is deleted from its cytoplasmic phosphorylatable domain. However, the expression of the non-phosphorylatable deletant of beta4 was associated with decreased transendothelial cell migration underscoring the key role for the cytoplasmic domain of beta4 in cell migration. We suggest: 1) that the adhesion of HT-29 cells to activated endothelial cells follows at least two essential sequential steps involving the binding of E-selectin to its receptor on carcinoma cells and then the binding of beta4 to its own receptor on endothelial cells; 2) that the phosphorylation of integrin beta4 contributes to enhance the motile potential of cancer cells and increase their trans-endothelial migration. Overall, our results indicate that the interaction of metastatic cancer cells with endothelial cells implies a specific sequence of signaling events that ultimately leads to an increase in their efficient transendothelial migration.
Liver Metastasis in Cancer: Molecular Mechanisms and Management.
Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J MedComm (2020). 2025; 6(3):e70119.
PMID: 40027151 PMC: 11868442. DOI: 10.1002/mco2.70119.
Establishment and application of a high-throughput screening model for cell adhesion inhibitors.
Sun H, Wang X, Li J, Tang M, Li H, Lei L Front Pharmacol. 2023; 14:1140163.
PMID: 36909195 PMC: 9995855. DOI: 10.3389/fphar.2023.1140163.
Cancer metastasis chemoprevention prevents circulating tumour cells from germination.
Xie X, Li Y, Lian S, Lu Y, Jia L Signal Transduct Target Ther. 2022; 7(1):341.
PMID: 36184654 PMC: 9526788. DOI: 10.1038/s41392-022-01174-w.
Hypoxia as a Modulator of Inflammation and Immune Response in Cancer.
Castillo-Rodriguez R, Trejo-Solis C, Cabrera-Cano A, Gomez-Manzo S, Davila-Borja V Cancers (Basel). 2022; 14(9).
PMID: 35565420 PMC: 9099524. DOI: 10.3390/cancers14092291.
Mori K, Higurashi M, Ishikawa F, Shibanuma M Cancer Sci. 2021; 112(8):3205-3217.
PMID: 34036687 PMC: 8353950. DOI: 10.1111/cas.14985.